SP
Pagano, Sabrina
Affiliation entities
Research groups
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Autoimmunity in MASLD : Focus on autoantibodies, anti‐apolipoprotein A1 IgG and G protein‐coupled receptors | European journal of clinical investigation | 2025 | 62 | 87 | |||
| Association between SARS-CoV-2 infection and anti-apolipoprotein A-1 antibody in children | Frontiers in immunology | 2025 | 47 | 47 | |||
| Autoantibodies to apolipoprotein A-I in hepatitis C virus infection : a role in disease progression? | Frontiers in immunology | 2025 | 32 | 23 | |||
| Faux positif lié à une macrotroponinémie élevée | Revue médicale suisse | 2024 | 95 | 0 | |||
| People living with HIV display increased anti-apolipoprotein A1 auto-antibodies, inflammation, and kynurenine metabolites : a case–control study | Frontiers in cardiovascular medicine | 2024 | 111 | 32 | |||
| Anti-apolipoprotein A-1 IgG, incident cardiovascular events, and lipid paradox in rheumatoid arthritis | Frontiers in cardiovascular medicine | 2024 | 110 | 126 | |||
| Linking Antibodies Against Apolipoprotein A-1 to Metabolic Dysfunction-Associated Steatohepatitis in Mice | International journal of molecular sciences | 2024 | 118 | 84 | |||
| Comment on: Humoral responses against HDL are linked to lipoprotein traits, atherosclerosis, inflammation and pathogenic pathways during early arthritis stages | Rheumatology | 2023 | 79 | 0 | |||
| Association of Trace Element Levels with Outcomes in Critically Ill COVID-19 Patients | Nutrients | 2023 | 696 | 669 | |||
| Antibody against apolipoprotein-A1, non-alcoholic fatty liver disease and cardiovascular risk: a translational study | Journal of translational medicine | 2023 | 134 | 92 | |||
| Impact of SARS-CoV2 infection on anti-apolipoprotein A-1 IgG response in inflammatory rheumatic diseases | Frontiers in immunology | 2023 | 128 | 70 | |||
| Serum Level of Cytokeratin 18 (M65) as a Prognostic Marker of High Cardiovascular Disease Risk in Individuals with Non-Alcoholic Fatty Liver Disease | Biomolecules | 2023 | 73 | 77 | |||
| Anti‐SARS-CoV‐2 mRNA vaccines as inducers of humoral response against apolipoprotein A‐1? | European journal of clinical investigation | 2022 | 241 | 129 | |||
| GPR55 in B cells limits atherosclerosis development and regulates plasma cell maturation | Nature cardiovascular research | 2022 | 212 | 31 | |||
| High antibody titers against apolipoprotein-A1 in NAFLD: a possible link between fatty liver disease and CVD? | 90th European Atherosclerosis Society (EAS) congress | 2022 | 152 | 0 | |||
| Transient elevation of humoral responses against apolipoprotein A-1 following COVID-19 and its association with symptoms persistence | 90th EAS (European Atherosclerosis Society) Congress | 2022 | 84 | 0 | |||
| Bariatric Surgery Leads to a Reduction in Antibodies to Apolipoprotein A-1: a Prospective Cohort Study | Obesity surgery | 2022 | 360 | 109 | |||
| Autoantibodies against apolipoprotein A-1 after COVID-19 predict symptoms persistence | European journal of clinical investigation | 2022 | 438 | 125 | |||
| Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA | RMD open | 2022 | 117 | 87 | |||
| Kinetics of inflammatory biomarkers to predict one-year mortality in older patients hospitalized for pneumonia: a multivariable analysis | International journal of infectious diseases | 2022 | 206 | 170 | |||
| SARS-COV2- infection as a trigger of humoral response against apolipoprotein A-1 | EAS Congress 2021 | 2021 | 372 | 38 | |||
| Anti‐ApoA‐1 IgGs predict resistance to waist circumference reduction after Mediterranean diet | European journal of clinical investigation | 2021 | 203 | 0 | |||
| Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses | The Lancet. Rheumatology | 2021 | 240 | 162 | |||
| SARS-CoV-2 infection as a trigger of humoral response against apolipoprotein A-1 | European Journal of Clinical Investigation | 2021 | 407 | 245 | |||
| Role of Clinical Characteristics and Biomarkers at Admission to Predict One-Year Mortality in Elderly Patients with Pneumonia | Journal of clinical medicine | 2021 | 265 | 151 | |||
| Autoantibodies directed against apolipoprotein-A1 as a potential contributor to Non-Alcoholic Fatty Liver Disease | 89th Europen Society of Atherosclerosis (EAS) | 2021 | 134 | 0 | |||
| Antibodies against apolipoprotein a-1 as disruptors of cellular cholesterol homeostasis promoting foam cell formation | 88th EAS (European Atherosclerosis Society) Congress | 2020 | 58 | 0 | |||
| Antiapolipoprotein A-1 Autoantibody Positivity Is Associated with Threatened Abortion | BioMed research international | 2020 | 176 | 102 | |||
| Identification of immunodominant linear epitopes from SARS-CoV-2 patient plasma | PLOS ONE | 2020 | 465 | 334 | |||
| Auto-antibodies against apolipoprotein a-1 block cancer cells proliferation and induce apoptosis | Oncotarget | 2020 | 169 | 115 | |||
| Atherosclerotic plaque vulnerability is increased in mouse model of lupus | Scientific Reports | 2020 | 320 | 201 | |||
| Prognostic and therapeutic considerations of antibodies against c‐ter apolipoprotein A‐1 in the general population | Clinical & translational immunology | 2020 | 201 | 123 | |||
| C-terminus apoa-1 mimetic peptides to detect cognate auto-antibodies and reverse HIV-induced foam cell formation | Atherosclerosis | 2020 | 244 | 0 | |||
| Antibodies against the C-terminus of apoA-1 are inversely associated with cholesterol efflux capacity and HDL metabolism in subjects with and without type 2 diabetes mellitus | International Journal of Molecular Sciences | 2019 | 385 | 201 | |||
| Autoantibodies to apolipoprotein A-1 as independent predictors of cardiovascular mortality in renal transplant recipients | Journal of Clinical Medicine | 2019 | 340 | 146 | |||
| Relationship between HDL Cholesterol Efflux Capacity, Calcium Coronary Artery Content, and Antibodies against ApolipoproteinA-1 in Obese and Healthy Subjects | Journal of clinical medicine | 2019 | 236 | 76 | |||
| Clinical, behavioral and biomarker predictors of PCSK9 levels in HIV-infected patients naïve of statin therapy: A cross-sectional analysis from the Swiss HIV cohort | Atherosclerosis | 2019 | 432 | 1 | |||
| Non-linear relationship between anti-apolipoprotein A-1 IgGs and cardiovascular outcomes in patients with acute coronary syndromes | Journal of Clinical Medicine | 2019 | 430 | 168 | |||
| Anti-apolipoprotein A-1 autoantibodies correlate with disease activity in systemic lupus erythematosus | Rheumatology | 2019 | 477 | 224 | |||
| Anti-ApoA-1 IgGs in Familial Hypercholesterolemia Display Paradoxical Associations with Lipid Profile and Promote Foam Cell Formation | Journal of clinical medicine | 2019 | 236 | 142 | |||
| P5343 - The presence of anti-apolipoprotein A1 autoantibodies is associated with a pro-atherogenic profile in HIV-infected patients | ESC Congress 2019 together with World Congress of Cardiology | 2019 | 115 | 0 | |||
| Association of novel biomarkers with major clinical outcomes in a cohort of patients with atherosclerotic renovascular disease | Annals of Clinical Biochemistry | 2019 | 348 | 0 | |||
| ELISA methods comparison for the detection of auto-antibodies against apolipoprotein A1 | Journal of Immunological Methods | 2019 | 385 | 1 | |||
| Deficiency of monoacylglycerol lipase enhances IgM plasma levels and limits atherogenesis in a CB2-dependent manner | Thrombosis and Haemostasis | 2019 | 423 | 0 | |||
| Humoral immunity against HDL particle: a new perspective in cardiovascular diseases? | Current Pharmaceutical Design | 2019 | 272 | 0 | |||
| Infection-induced humoral autoimmunity: a missing link in the interplay between pathogens, dyslipidemia, and innate immunity? | Journal of the American College of Cardiology | 2018 | 298 | 0 | |||
| Anti-apolipoprotein A-1 autoantibodies are associated with immunodeficiency and systemic inflammation in HIV patients | Journal of Infection | 2018 | 575 | 1 | |||
| Autoantibody to apolipoprotein A-1 in hepatitis C virus infection: a role in atherosclerosis? | Hepatology International | 2018 | 438 | 224 | |||
| Anti-Apolipoprotein A-1 IgG Predict All-Cause Mortality and Are Associated with Fc Receptor-Like 3 Polymorphisms | Frontiers in Immunology | 2017 | 467 | 218 | |||
| Impact of CD14 Polymorphisms on Anti-Apolipoprotein A-1 IgG-Related Coronary Artery Disease Prediction in the General Population | Arteriosclerosis, Thrombosis, and Vascular Biology | 2017 | 514 | 0 | |||
| Vitamin D receptor is expressed within human carotid plaques and correlates with pro-inflammatory M1 macrophages | Vascular pharmacology | 2016 | 555 | 0 | |||
| Association between anti-apolipoprotein A-1 antibodies and cardiovascular disease in the general population. Results from the CoLaus study | Thrombosis and haemostasis | 2016 | 562 | 7 | |||
| The Associations of Blood Kidney Injury Molecule-1 and Neutrophil Gelatinase-Associated Lipocalin with Progression from CKD to ESRD | Clinical Journal of the American Society of Nephrology | 2016 | 418 | 0 | |||
| Anti-apolipoprotein A-1 auto-antibodies as active modulators of atherothrombosis | Thrombosis and haemostasis | 2016 | 758 | 595 | |||
| Diagnostic and prognostic value of autoantibodies anti-apolipoprotein A-1 and anti-phosphorylcholine in acute non-ST elevation myocardial infarction | European journal of clinical investigation | 2015 | 629 | 3 | |||
| CD14 as a Mediator of the Mineralocorticoid Receptor-Dependent Anti-apolipoprotein A-1 IgG Chronotropic Effect on Cardiomyocytes | Endocrinology | 2015 | 664 | 1 | |||
| The Human Autoantibody Response to Apolipoprotein A-I Is Focused on the C-Terminal Helix: A New Rationale for Diagnosis and Treatment of Cardiovascular Disease? | PloS one | 2015 | 554 | 325 | |||
| Treatment with sulphated galactan inhibits macrophage chemotaxis and reduces intraplaque macrophage content in atherosclerotic mice | Vascular pharmacology | 2015 | 606 | 0 | |||
| Definition of human apolipoprotein A-I epitopes recognized by autoantibodies present in patients with cardiovascular diseases | The Journal of biological chemistry | 2014 | 761 | 628 | |||
| 18FDG-PET-CT: an imaging biomarker of high-risk carotid plaques. Correlation to symptoms and microembolic signals | Stroke | 2014 | 709 | 3 | |||
| Anti-apolipoprotein A-1 autoantibodies as biomarker for atherosclerosis burden in patients with periodontitis | Journal of periodontal research | 2013 | 771 | 1 | |||
| Serum levels of anti-apolipoprotein A-1 auto-antibodies and myeloperoxidase as predictors of major adverse cardiovascular events after carotid endarterectomy | Thrombosis and haemostasis | 2013 | 734 | 1 | |||
| Auto-antibodies as Emergent Prognostic Markers and Possible Mediators of Ischemic Cardiovascular Diseases | Clinical reviews in allergy & immunology | 2013 | 643 | 3 | |||
| Anti-apolipoprotein A-1 IgG levels predict coronary artery calcification in obese but otherwise healthy individuals | Mediators of inflammation | 2012 | 650 | 269 | |||
| Anti-apolipoprotein A-1 IgG in patients with myocardial infarction promotes inflammation through TLR2/CD14 complex | Journal of internal medicine | 2012 | 745 | 3 | |||
| Evaluation of cardiovascular risk in patients with rheumatoid arthritis: do cardiovascular biomarkers offer added predictive ability over established clinical risk scores? | Arthritis care & research | 2012 | 692 | 0 | |||
| High prevalence of anti-apolipoprotein/A-1 autoantibodies in maintenance hemodialysis and association with dialysis vintage | Therapeutic apheresis and dialysis | 2012 | 641 | 0 | |||
| Autoantibodies against apolipoprotein A-1 and phosphorylcholine for diagnosis of non-ST-segment elevation myocardial infarction | Journal of internal medicine | 2012 | 666 | 2 | |||
| The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques | European heart journal | 2012 | 735 | 0 | |||
| Receptor activator of NF- κB ligand (RANKL) increases the release of neutrophil products associated with coronary vulnerability | Thrombosis and haemostasis | 2012 | 791 | 0 | |||
| Antiapolipoprotein A-1 IgG chronotropic effects require nongenomic action of aldosterone on L-type calcium channels | Endocrinology | 2012 | 705 | 0 | |||
| Anti-Apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability | European heart journal | 2011 | 671 | 2 | |||
| Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis | Arthritis and rheumatism | 2010 | 899 | 3 | |||
| Anti-apolipoprotein A-1 IgG as an independent cardiovascular prognostic marker affecting basal heart rate in myocardial infarction | European heart journal | 2010 | 701 | 0 |
